Beta Bionics director plans sale of 8,942 shares

Beta Bionics, Inc. (BBNX) director Christina Jones filed a Rule 144 notice indicating an intention to sell up to 8,942 shares of common stock of Beta Bionics through Morgan Stanley Smith Barney LLC on NASDAQ.

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) director Christina Jones filed a Rule 144 notice indicating an intention to sell up to 8,942 shares of common stock of Beta Bionics through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were and will be acquired upon the exercise of stock options and settlement of restricted stock units over the next three months.

Key Figures

Shares to be sold under Rule 144: 8,942 shares Aggregate market value of planned sale: $197,081.68 Shares from stock option exercise: 7,536 shares +2 more

5 metrics

Shares to be sold under Rule 144 8,942 shares Common stock of Beta Bionics to be sold through Morgan Stanley Smith Barney LLC

Aggregate market value of planned sale $197,081.68 Value of 8,942 Beta Bionics shares as of September 22, 2026

Shares from stock option exercise 7,536 shares Common stock acquired from exercise of stock options dated March 2, 2023

Shares from restricted stock units 1,406 shares Common stock from restricted stock units dated December 1, 2025

Recent 10b5-1 sale 1,406 shares for $21,090.00 Common stock sold on June 24, 2026 by Christina Jones under a 10b5-1 plan

Key Terms

Rule 144, Restricted Stock Units, Exercise of Stock Options, 10b5-1

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 12/01/2025 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Exercise of Stock Options financial

"Common | 03/02/2023 | Exercise of Stock Options | Issuer"

10b5-1 regulatory

"10b5-1 Sales for CHRISTINA JONES 11 Hughes Irvine CA 92618"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing reveal about planned sales of BBNX shares?

The filing shows that director Christina Jones plans a potential sale of up to 8,942 shares of Beta Bionics common stock under Rule 144, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

What is the estimated market value of the BBNX shares covered by this Form 144?

The notice lists 8,942 shares of Beta Bionics common stock with an aggregate market value of $197,081.68 as of September 22, 2026.

How were the Beta Bionics (BBNX) shares to be sold by Christina Jones acquired?

The shares were and will be received upon the exercise of stock options dated March 2, 2023 for 7,536 shares and from restricted stock units dated December 1, 2025 for 1,406 shares.

What BBNX share sales has Christina Jones made in the past three months?

The filing reports that under a 10b5-1 plan, Christina Jones sold 1,406 shares of Beta Bionics common stock on June 24, 2026 for total proceeds of $21,090.00.

Who is the broker for the planned Beta Bionics (BBNX) Rule 144 sale?

The planned sale of 8,942 shares of Beta Bionics common stock will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York.

What does the remark about option exercises mean for the BBNX Form 144 filing?

The remark states that the securities to be sold were and will be received upon the exercise of stock options over the next three months, and that the acquisition and payment dates are and will be the dates of exercise or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:15 PM Accepted by SEC EDGAR 09/22/2026 - 04:15 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002048467
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BETA BIONICS INC
SEC File Number	001-42491
Address of Issuer	11 Hughes Irvine CALIFORNIA 92618
Phone	9494277785
Name of Person for Whose Account the Securities are To Be Sold	CHRISTINA JONES
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8942	197081.68	44989688	09/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/02/2023	Exercise of Stock Options	Issuer			7536	03/02/2023	Cash
Common	12/01/2025	Restricted Stock Units	Issuer			1406	12/01/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for CHRISTINA JONES 11 Hughes Irvine CA 92618	Common	06/24/2026	1406	21090.00

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	09/22/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Christina Jones
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)